JP2013534313A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013534313A5 JP2013534313A5 JP2013522346A JP2013522346A JP2013534313A5 JP 2013534313 A5 JP2013534313 A5 JP 2013534313A5 JP 2013522346 A JP2013522346 A JP 2013522346A JP 2013522346 A JP2013522346 A JP 2013522346A JP 2013534313 A5 JP2013534313 A5 JP 2013534313A5
- Authority
- JP
- Japan
- Prior art keywords
- hmgb1
- antibody
- stool sample
- protein
- ibd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000284 extract Substances 0.000 claims description 7
- 230000002550 fecal effect Effects 0.000 claims description 7
- 238000001262 western blot Methods 0.000 claims description 7
- 101001025337 Homo sapiens High mobility group protein B1 Proteins 0.000 claims description 6
- 102000053637 human HMGB1 Human genes 0.000 claims description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 4
- 210000004408 hybridoma Anatomy 0.000 claims description 4
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 241000588724 Escherichia coli Species 0.000 claims description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 11
- 102000055207 HMGB1 Human genes 0.000 claims 9
- 108700010013 HMGB1 Proteins 0.000 claims 9
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 8
- 238000004737 colorimetric analysis Methods 0.000 claims 6
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 claims 5
- 101150021904 HMGB1 gene Proteins 0.000 claims 5
- 208000011231 Crohn disease Diseases 0.000 claims 4
- 238000012286 ELISA Assay Methods 0.000 claims 4
- 230000004968 inflammatory condition Effects 0.000 claims 4
- 230000000968 intestinal effect Effects 0.000 claims 3
- 238000009010 Bradford assay Methods 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 238000005119 centrifugation Methods 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 238000011156 evaluation Methods 0.000 claims 2
- 238000000605 extraction Methods 0.000 claims 2
- 239000011536 extraction buffer Substances 0.000 claims 2
- 238000000265 homogenisation Methods 0.000 claims 2
- 230000002163 immunogen Effects 0.000 claims 2
- 210000000936 intestine Anatomy 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 238000005259 measurement Methods 0.000 claims 2
- 239000006228 supernatant Substances 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- 238000007398 colorimetric assay Methods 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 235000013861 fat-free Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITRM2010A000442A IT1406051B1 (it) | 2010-08-05 | 2010-08-05 | Uso di hmgb1 come marcatore biologico di infiammazione intestinale umana, metodo non invasivo per la sua rilevazione in campioni fecali e kit relativo. |
| ITRM2010A000442 | 2010-08-05 | ||
| PCT/IT2011/000276 WO2012017466A1 (en) | 2010-08-05 | 2011-08-01 | Use of hmgb1 as' a biological marker of bowel inflammatory conditions, non-invasive method for its detection in fecal samples and kit thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013534313A JP2013534313A (ja) | 2013-09-02 |
| JP2013534313A5 true JP2013534313A5 (enExample) | 2014-09-18 |
Family
ID=43739596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013522346A Pending JP2013534313A (ja) | 2010-08-05 | 2011-08-01 | 腸の炎症状態の生物学的マーカーとしてのｈｍｇｂ１の使用、糞便サンプル中のｈｍｇｂ１を検出するための非侵襲法およびそのキット |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20130137123A1 (enExample) |
| EP (1) | EP2601525A1 (enExample) |
| JP (1) | JP2013534313A (enExample) |
| CN (1) | CN103069276A (enExample) |
| AU (1) | AU2011287193B2 (enExample) |
| BR (1) | BR112013002145A2 (enExample) |
| CA (1) | CA2807107C (enExample) |
| CL (1) | CL2013000223A1 (enExample) |
| EA (1) | EA201390197A1 (enExample) |
| IL (1) | IL223845A (enExample) |
| IT (1) | IT1406051B1 (enExample) |
| MX (1) | MX2013001327A (enExample) |
| PE (1) | PE20131062A1 (enExample) |
| WO (1) | WO2012017466A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015067913A1 (en) | 2013-11-07 | 2015-05-14 | Diagnodus Limited | Biomarkers |
| PT2968443T (pt) | 2013-03-15 | 2021-12-28 | Protagonist Therapeutics Inc | Análogos de hepcidina e seus usos |
| SG10201810321PA (en) | 2014-05-16 | 2018-12-28 | Protagonist Therapeutics Inc | α4β7 INTEGRIN THIOETHER PEPTIDE ANTAGONISTS |
| ES2977537T3 (es) | 2014-07-17 | 2024-08-26 | Protagonist Therapeutics Inc | Inhibidores peptídicos orales del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias intestinales |
| WO2017117411A1 (en) | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| WO2018089693A2 (en) * | 2016-11-09 | 2018-05-17 | Protagonist Therapeutics, Inc. | Methods for determining and monitoring gastrointestinal inflammation |
| DK3622082T3 (da) | 2017-05-12 | 2023-06-12 | Evonik Operations Gmbh | Fremgangsmåde til påvisning af c. perfringens-inducerede sygdomme i en fugleflok |
| IT201700083044A1 (it) | 2017-07-20 | 2019-01-20 | Laura Stronati | “uso della gelsolina come marcatore diagnostico e prognostico delle malattie infiammatorie intestinali” |
| IT201700083055A1 (it) | 2017-07-20 | 2019-01-20 | Laura Stronati | “uso della proteina inibitore 2 della dissociazione di rho gdp come marcatore diagnostico e prognostico delle malattie infiammatorie intestinali” |
| EP4501952A3 (en) | 2018-02-08 | 2025-04-16 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| CA3092472A1 (en) * | 2018-03-02 | 2019-09-06 | Evonik Operations Gmbh | In vitro method for detecting intestinal barrier failure in animals |
| CN109030817A (zh) * | 2018-07-04 | 2018-12-18 | 长沙都正医学检验有限责任公司 | Hmgb1检测试剂盒及其制备方法 |
| ES2938227T3 (es) | 2018-12-14 | 2023-04-05 | Evonik Operations Gmbh | Método in vitro de detección de disbiosis intestinal aviar |
| US11684653B2 (en) * | 2019-03-06 | 2023-06-27 | The Cleveland Clinic Foundation | Compositions and method for reducing virulence of microorganisms |
| CN115279782A (zh) | 2020-01-15 | 2022-11-01 | 詹森生物科技公司 | 白介素-23受体的肽抑制剂及其用于治疗炎性疾病的用途 |
| IL294680A (en) | 2020-01-15 | 2022-09-01 | Janssen Biotech Inc | Peptide inhibitors of the interleukin-23 receptor and their use for the treatment of inflammatory diseases |
| IL302996B2 (en) | 2020-11-20 | 2025-04-01 | Janssen Pharmaceutica Nv | Compositions of interleukin-23 receptor peptide inhibitors |
| AU2022311814A1 (en) | 2021-07-14 | 2024-02-29 | Janssen Biotech, Inc. | Lipidated peptide inhibitors of interleukin-23 receptor |
| CN116973572B (zh) * | 2023-06-02 | 2025-03-07 | 东南大学附属中大医院 | 基于血、粪便铁蛋白检测评估肠屏障损伤严重程度的方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1577671A1 (en) * | 1996-07-17 | 2005-09-21 | Kaneka Corporation | Diagnostic drugs for autoimmune diseases |
| US6355623B2 (en) * | 1998-09-24 | 2002-03-12 | Hopital-Sainte-Justine | Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage |
| US6303321B1 (en) * | 1999-02-11 | 2001-10-16 | North Shore-Long Island Jewish Research Institute | Methods for diagnosing sepsis |
| EP1601969A2 (en) * | 2003-03-08 | 2005-12-07 | Auvation Ltd | Markers for colorectal cancer |
| WO2007001422A2 (en) * | 2004-10-22 | 2007-01-04 | Medimmune, Inc. | High affinity antibodies against hmgb1 and methods of use thereof |
| WO2008075788A1 (ja) * | 2006-12-20 | 2008-06-26 | Shino-Test Corporation | ヒトｈｍｇｂ１と特異的に結合する鳥類由来の抗体、ヒトｈｍｇｂ１の免疫学的測定方法及びヒトｈｍｇｂ１の免疫学的測定試薬 |
| EP2185936A4 (en) * | 2007-08-02 | 2010-08-04 | Iss Immune System Stimulation | DIAGNOSIS, STADIFICATION AND SURVEILLANCE OF INFLAMMATORY ABDOMINAL DISEASE |
| US7833721B2 (en) * | 2008-03-14 | 2010-11-16 | Exagen Diagnostics, Inc. | Biomarkers for inflammatory bowel disease and irritable bowel syndrome |
-
2010
- 2010-08-05 IT ITRM2010A000442A patent/IT1406051B1/it active
-
2011
- 2011-08-01 JP JP2013522346A patent/JP2013534313A/ja active Pending
- 2011-08-01 CN CN2011800327624A patent/CN103069276A/zh active Pending
- 2011-08-01 AU AU2011287193A patent/AU2011287193B2/en not_active Ceased
- 2011-08-01 EA EA201390197A patent/EA201390197A1/ru unknown
- 2011-08-01 WO PCT/IT2011/000276 patent/WO2012017466A1/en not_active Ceased
- 2011-08-01 US US13/814,294 patent/US20130137123A1/en not_active Abandoned
- 2011-08-01 BR BR112013002145A patent/BR112013002145A2/pt not_active IP Right Cessation
- 2011-08-01 EP EP11754539.2A patent/EP2601525A1/en not_active Withdrawn
- 2011-08-01 PE PE2013000131A patent/PE20131062A1/es not_active Application Discontinuation
- 2011-08-01 MX MX2013001327A patent/MX2013001327A/es unknown
- 2011-08-01 CA CA2807107A patent/CA2807107C/en not_active Expired - Fee Related
-
2012
- 2012-12-24 IL IL223845A patent/IL223845A/en active IP Right Grant
-
2013
- 2013-01-23 CL CL2013000223A patent/CL2013000223A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013534313A5 (enExample) | ||
| JP7022969B2 (ja) | ＳＡＲＳ－ＣｏＶ－２感染症を診断するための方法および試薬 | |
| WO2022077613A1 (zh) | 一种新型冠状病毒 s 蛋白的 b 细胞线性抗原表位、抗体、鉴定方法及应用 | |
| JP2013534313A (ja) | 腸の炎症状態の生物学的マーカーとしてのｈｍｇｂ１の使用、糞便サンプル中のｈｍｇｂ１を検出するための非侵襲法およびそのキット | |
| Muralidharan et al. | Development of an enzyme-linked immunosorbent assay for detecting Campylobacter hepaticus specific antibodies in chicken sera–a key tool in Spotty Liver Disease screening and vaccine development | |
| CA3033035A1 (en) | Method for the diagnosis of acute pancreatitis (ap) by detection of glycoprotein 2 isoform alpha (gp2a) | |
| US12352766B2 (en) | Immunoassay method for free aim in biological sample, and method for detecting NASH in subject | |
| CN104928257A (zh) | 分泌沙门菌SpiC蛋白单克隆抗体的杂交瘤细胞株、其单克隆抗体及其应用 | |
| Jeong et al. | Monoclonal antibodies to recombinant Der f 2 and development of a two‐site ELISA sensitive to major Der f 2 isoallergen in Korea | |
| JP5204036B2 (ja) | 肺炎球菌の検出方法 | |
| EP2913675B1 (en) | GP2 isoforms and their use in autoantibody capture | |
| Cooper et al. | ELISA and immuno–polymerase chain reaction assays for the sensitive detection of melioidosis | |
| US20180244734A1 (en) | Novel proteins and detection methods | |
| CA2876916A1 (en) | Kit for diagnosing malignant melanoma | |
| CN110476065B (zh) | 诊断法 | |
| CN103421747B (zh) | 分泌牛il-4单克隆抗体的杂交瘤细胞株、其单克隆抗体及其应用 | |
| FR2966461A1 (fr) | Utilisation d'anticorps anti-vp2 du btv-8 pour le serotypage et le diagnostic des infections a btv | |
| WO2020245663A1 (en) | Nanobody-based ns1 assay for the specific diagnosis of acute zika virus infection | |
| Pandey et al. | Antigen detection assay with parasite specific monoclonal antibodies for diagnosis of lymphatic filariasis | |
| CN111378628A (zh) | 一种分泌结核分枝杆菌esat6蛋白特异性抗体的杂交瘤细胞株、其抗体及应用 | |
| JP2006199655A (ja) | Ｎ１，ｎ１２−ジアセチルスペルミンに対する高親和性モノクローナル抗体 | |
| CN101654668B (zh) | 杂交瘤细胞株及其产生抗广州管圆线虫v期幼虫55kd抗原单克隆抗体 | |
| US20220390449A1 (en) | New serological marker for the latent form of toxoplasmosis | |
| US20140271701A1 (en) | Use of mycobacterium avium paratuberculosis peptides to diagnose type 1 diabetes | |
| Zhang et al. | Soluble expression and purification of Brucella cell surface protein (BCSP31) of Brucella melitensis and preparation of anti-BCSP31 monoclonal antibodies |